Summary & Overview

CPT 0008U: H. pylori Antibiotic Resistance Panel, Gene Sequence Analysis

CPT code 0008U designates a Proprietary Laboratory Analyses (PLA) test: the AmHPR Helicobacter pylori Antibiotic Resistance Panel by American Molecular Laboratories, Inc. This sequencing-based molecular assay evaluates fresh tissue or fecal specimens to identify H. pylori resistance to antibiotics, informing antimicrobial management and public health surveillance. As a PLA code, 0008U maps to one manufacturer-specific test and is important for laboratory billing clarity and payer coverage determinations nationwide.

Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines payer coverage patterns, coding and billing considerations for PLA-coded molecular diagnostics, and how this test fits into clinical pathways for diagnosing and managing H. pylori infection.

Readers will find benchmarks and contextual policy discussion relevant to PLA molecular diagnostics, a summary of clinical context for sequencing-based antibiotic resistance testing, and practical information about where the service is typically performed. The content focuses on national implications for billing, coding specificity inherent to PLA codes, and factors payers consider when evaluating coverage for targeted molecular resistance assays.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicare0008UCPTProprietary Laboratory Analysesmolecular diagnosticsHelicobacter pyloriantibiotic resistancesequencinglaboratory billing

Billing Code Overview

CPT code 0008U is a Proprietary Laboratory Analyses (PLA) code that describes the AmHPR Helicobacter pylori Antibiotic Resistance Panel produced by American Molecular Laboratories, Inc. The service is a gene sequence analysis performed to detect antibiotic resistance in Helicobacter pylori using a fresh tissue specimen or a fecal specimen.

Service Type: Laboratory — molecular diagnostic, sequencing-based antimicrobial resistance testing

Typical Site of Service: Clinical laboratory or reference laboratory processing specimens collected in outpatient clinics, inpatient facilities, or ambulatory settings

Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.

Clinical & Coding Specifications

Clinical Context

A 42-year-old patient presents with persistent dyspepsia and recent positive noninvasive testing for Helicobacter pylori infection. The treating gastroenterologist prescribes eradication therapy but wants to determine antibiotic susceptibility because the patient has had prior macrolide exposure and failed empirical therapy previously. During colonization assessment, the clinician obtains a fresh gastric biopsy specimen during upper endoscopy or collects a fresh fecal specimen for molecular testing. The specimen is sent to American Molecular Laboratories, Inc. for the AmHPR Helicobacter pylori Antibiotic Resistance Panel (0008U), a gene sequence analysis that identifies H. pylori antibiotic resistance markers to guide targeted therapy.

Typical clinical workflow:

The patient is evaluated in outpatient gastroenterology or primary care for symptoms suggestive of H. pylori infection.
Noninvasive testing (urea breath test, stool antigen) or endoscopic biopsy confirms infection or is clinically indicated; if resistance testing is needed, a fresh tissue or fecal specimen is collected.
Specimen handling follows laboratory instructions for preservation and transport to the performing laboratory.
The laboratory performs gene sequence analysis for known H. pylori resistance mutations and reports antibiotic resistance profile to the ordering clinician.
The clinician uses the report to select an appropriate antibiotic regimen and documents the test result and therapeutic decision in the medical record.

Typical site of service: outpatient gastroenterology clinic with endoscopy suite or outpatient specimen collection/clinical laboratory; specimens may originate from inpatient endoscopy when clinically indicated.

Service type: Proprietary Laboratory Analysis (PLA) — molecular diagnostic gene sequencing for pathogen antibiotic resistance.

Coding Specifications

Modifier	Description	When to Use
`00`	Unspecified modifier	Rarely used; reserved if payer requires a placeholder when no other modifier applies.
`11`	Judicially not a standard CMS modifier; in this input set used as default/placeholder	Use only if payer-specific guidance requires this code (rare).
`22`	Increased procedural services	When the laboratory documents substantially greater work than typical for the test (rare for PLA codes; use per payer rules).
`26`	Professional component	When billing is split and the physician/lab bills only the professional interpretation component (use with technical component `TC` if applicable).
`52`	Reduced services	If the test is completed but a portion of the usual service is not performed.
`53`	Discontinued procedure	If specimen collection or testing was discontinued for documented reasons prior to completion.
`62`	Two surgeons	Not typically applicable to this laboratory test; include only if two qualified providers share responsibility per payer policy.
`78`	Unplanned return to the operating/procedure room	Not applicable to the lab test itself; relevant if endoscopy requires reoperation.
`80`	Assistant surgeon	Not applicable to the laboratory analysis; relevant to procedural billing at time of biopsy.
`QK`	Medical direction of two or more CRNAs	Not applicable to lab billing; included for comprehensive modifier awareness.
`QX`	CRNA service with medical direction by physician	Not applicable to lab billing; see facility/endoscopy billing.

Taxonomy Code	Specialty	Notes
`208800000X`	Gastroenterology	Gastroenterologists obtain gastric biopsies and order H. pylori resistance testing.
`207Q00000X`	Pathology & Laboratory Medicine	Pathologists and laboratory directors oversee molecular testing and reporting.
`363A00000X`	Clinical Laboratory	Clinical laboratory specialists and molecular diagnosticians perform sequencing and interpretation.
`208000000X`	Family Medicine	Primary care physicians may order stool-based molecular H. pylori resistance testing and manage treatment.
`207L00000X`	Infectious Disease	Infectious disease specialists interpret resistance profiles for complex or refractory cases.

ICD-10 Code	Description	Clinical Relevance
`K29.70`	Gastritis, unspecified, without bleeding	Symptom complex prompting endoscopy and testing for H. pylori and potential resistance profiling.
`K29.50`	Gastritis, unspecified, with hemorrhage	When gastric inflammation with bleeding prompts biopsy and testing to guide eradication therapy.
`K25.9`	Gastric ulcer, unspecified	Peptic ulcer disease associated with H. pylori infection; resistance testing can guide eradication in ulcer management.
`K27.9`	Peptic ulcer, site unspecified, without hemorrhage or perforation	H. pylori is a common etiologic factor; resistance data support appropriate antibiotic selection.
`A04.6`	Infection due to Clostridium difficile	Included as a differential diagnosis for antibiotic-associated diarrhea; stool testing pathways may overlap when stool specimens are collected.

CPT Code	Description	Relationship to This Procedure
`43239`	Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple	Endoscopic procedure to obtain gastric biopsy specimens that may be submitted for `0008U` testing.
`88305`	Level IV surgical pathology, gross and microscopic examination	Histologic evaluation of biopsy tissue; often performed on the same specimen before or alongside molecular testing.
`87480`	Infectious agent antigen detection by immunoassay, Helicobacter pylori; stool	Non-molecular stool antigen test used for initial diagnosis; may precede resistance testing.
`81299`	Unlisted molecular pathology procedure	Alternate coding if a payer does not recognize the PLA code; used per payer guidance (not preferred when `0008U` applies).
`87045`	Culture, bacterial; other source, quantitative, with isolation and presumptive identification	Culture-based methods for H. pylori and antibiotic susceptibility testing; may be performed when available to corroborate molecular resistance findings.

OpenPayer